Drug Trial Radar · NCT04975178
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
7,120
Planned (sponsor's estimate)
Start
Oct 17, 2022
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Biofabri, S.LIndustry
- Sponsor type
- Industry
- Collaborators
- TuBerculosis Vaccine Initiative; University of Cape Town; Institut Pasteur de Madagascar; Biomedical Research Center EPLS; Universidad de Zaragoza; University of Stellenbosch; University of KwaZulu; Wits Health Consortium (Pty) Ltd
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 minutes, up to 7 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccination. The proposal builds upon a group of TB vaccine development partners in Europe and sub-Saharan Africa established in a previous EDCTP-supported project. It creates an expanded consortium of clinical trial partners for the optimal implementation of a large infant efficacy trial of MTBVAC in high TB incidence settings. New capacity for efficacy trials in infants will be a valuable resource for the TB vaccine development community. The proposal will create a network of institutions in three TB endemic African countries with enhanced laboratory capacity to conduct TB vaccine immunology studies and to bio-bank samples to discover immune correlates of vaccine-mediated protection.
Conditions
- Tuberculosis
Interventions
MTBVACBiological
MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
BCGBiological
BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate efficacy in terms of incidence of MTBVAC against TB disease in healthy HU and HEU newborns compared to BCGTime frame: Minimum of 24 months to a maximum 80 months; or until study end in South Africa.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
South African Tuberculosis Initiative, Brewelskloof Hospital
Worcester, Western Cape, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.